Ashton-Rickardt Philip 4
4 · Sigilon Therapeutics, Inc. · Filed Jul 2, 2021
Insider Transaction Report
Form 4
Ashton-Rickardt Philip
Chief Scientific Officer
Transactions
- Award
Stock Option (Right to Buy)
2021-07-01+90,000→ 90,000 totalExercise: $10.61Exp: 2031-06-13→ Common Stock (90,000 underlying)
Footnotes (1)
- [F1]The option vest as to 25% of the underlying shares of common stock on June 14, 2022, the first anniversary of the vesting commencement date, and at a rate of 6.25% of the underlying shares thereafter on the first day of each quarter following such date until the option is fully vested.